Thymosin Alpha 1 5mg

Thymosin alpha-1 and immune regulation

Thymosin Alpha 1 5mg relates to a 28-amino-acid peptide derived from prothymosin-alpha. Its synthetic form, thymalfasin, has a research history spanning cellular immune responses and clinical investigations of immunomodulation.

Cellular processes under investigation

Laboratory work has examined T-cell differentiation, cytokine-related activity and antigen presentation. These processes help determine how immune cells recognise and respond to signals, giving thymosin alpha-1 a more specific scientific context than a general claim of increasing immunity.

The range of cellular effects has encouraged investigation in disease settings where immune regulation may matter. Translating those mechanisms into clinical benefit depends on the population, timing and outcome being studied.

Learning from clinical trials

The large, multicentre TESTS study investigated thymosin alpha-1 in adults with sepsis. Published in 2025 and subsequently corrected, it did not establish an overall reduction in 28-day mortality. Its findings help refine the clinical research questions and emphasise the need to distinguish mechanistic activity from patient outcomes.

Thymalfasin is associated with the medicine brand Zadaxin, which can be useful when locating its research history. This 5mg vial is a research listing, rather than an identified Zadaxin formulation.

Also known as / branded as

• Thymosin alpha-1
• Thymosin α1
• Tα1
• Tα-1
• TA1
• Thymalfasin
• Zadaxin (brand of a thymalfasin medicine)